
Patrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


Patrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.